FDA approves Lundbeck's schizophrenia treatment for teenagers
Following the green light from US health authorities, schizophrenia treatment Rexulti may now be used in patients as young as 13 years in the US.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
On Thursday, Lundbeck and partner Otsuk received the green light from the US Food and Drug Administration (FDA) to expand the use of the schizophrenia treatment to include patients aged 13 to 17 years, reports a shared press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck broadens phase III trial of Vyepti in children
For subscribers
